SkinBioTherapeutics (LON:SBTX) Announces Quarterly Earnings Results

SkinBioTherapeutics (LON:SBTX) released its earnings results on Monday. The company reported GBX (0.31) earnings per share for the quarter, Digital Look Earnings reports. The business had revenue of GBX 217 million during the quarter. SkinBioTherapeutics had a negative return on equity of 10.01% and a negative net margin of 15.01%.

SkinBioTherapeutics Stock Performance

Shares of LON:SBTX opened at GBX 9.75 on Monday. The firm’s 50 day simple moving average is GBX 9.73 and its 200-day simple moving average is GBX 12.80. The company has a debt-to-equity ratio of 10.55, a quick ratio of 10.01 and a current ratio of 4.84. SkinBioTherapeutics has a one year low of GBX 5 and a one year high of GBX 27.50. The firm has a market cap of £25.27 million, a PE ratio of -31.45 and a beta of 0.47.

SkinBioTherapeutics Company Profile

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.